Enterprise Value
39.1B
Cash
1.292B
Avg Qtr Burn
-147.5M
Short % of Float
7.91%
Insider Ownership
0.92%
Institutional Own.
85.40%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PADCEV® Details Urothelial carcinoma | Approved Quarterly sales | |
TUKYSA (Tucatinib) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer | Approved Quarterly sales | |
TIVDAK (tisotumab vedotin-tftv) Details Cervical cancer | Approved Quarterly sales | |
ADCETRIS® (Brentuximab Vedotin) Details Hodgkin Lymphoma | Approved Quarterly sales | |
Phase 3 Update | ||
TUKYSA (Tucatinib) combo Kadcyla Details Solid tumor/s, Cancer, Breast cancer | Phase 3 Update | |
ADCETRIS® + pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Melanoma | Phase 2 Data readout |